Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2007

Argos Licenses T-Cell Technology to Therakos

  • Argos Therapeutics signed an exclusive licensing agreement with Therakos, a Johnson & Johnson company, for the research and development of new treatments based on Argos’ regulatory T-cell technology.

    Argos is actively developing immunotherapies or indications such as cancer, infectious diseases, autoimmune disorders,  and transplantation using its Arcelis technology, which trains the immune system to recognize and attack the disease.

    “The licensing agreement with Therakos will enable accelerated development of an asset outside our primary focus, while providing Argos with nondilutive financial resources,” said John Bonfiglio, Ph.D., president and CEO at Argos Therapeutics. “This transaction further demonstrates our ability to leverage Argos´ leading immunotherapy science both through our own programs as well as through collaborations with select corporate partners."



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »